{"organizations": [], "uuid": "fd7e3a667bf8cb66a372a0e879ab842c7145ccc9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-summit-completes-dosing-of-ezutrom/brief-summit-completes-dosing-of-ezutromid-in-phaseout-dmd-clinical-trial-idUSASC09WG9", "country": "US", "domain_rank": 408, "title": "BRIEF-Summit Completes Dosing Of Ezutromid In Phaseout Dmd Clinical Trial", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-19T14:18:00.000+03:00", "replies_count": 0, "uuid": "fd7e3a667bf8cb66a372a0e879ab842c7145ccc9"}, "author": "", "url": "https://www.reuters.com/article/brief-summit-completes-dosing-of-ezutrom/brief-summit-completes-dosing-of-ezutromid-in-phaseout-dmd-clinical-trial-idUSASC09WG9", "ord_in_thread": 0, "title": "BRIEF-Summit Completes Dosing Of Ezutromid In Phaseout Dmd Clinical Trial", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": " Summit Completes Dosing Of Ezutromid In Phaseout Dmd Clinical Trial Reuters Staff \n  Summit Therapeutics PLC: \n* SUMMIT COMPLETES DOSING OF EZUTROMID IN PHASEOUT DMD CLINICAL TRIAL \n* SUMMIT THERAPEUTICS PLC - TOP-LINE DATA FROM FULL TRIAL CONTINUE TO BE EXPECTED IN Q3 2018   (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-04-19T14:18:00.000+03:00", "crawled": "2018-04-19T14:38:20.056+03:00", "highlightTitle": ""}